Latest news with #MedX
National Post
22-05-2025
- Business
- National Post
MedX Announces Further Closing of Non-Brokered Private Placement
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, announcing an Initial Closing, it has completed a further Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Further Closing comprised the issuance of 7,300,000 Units (as described below) and raised cash proceeds of $511,000, bringing the total amount raised so far to $1,456,000. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Further Closing(s) of the Placement will be subject to receipt of further subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Under this Non-Brokered Private Placement, the Company intends issue of up to a maximum of 35,714,858 Units at $0.07 per Unit ('Unit') to raise a Maximum amount of $2,500,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant (s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent's warrants (' Agent's Warrant(s) ') equal to 8% of subscriptions introduced by such agent(s). Each Agent's Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Article content Article content Funds raised in this Placement will be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. Article content About MedX Health Corp.: Article content MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
22-05-2025
- Business
- Business Wire
MedX Announces Further Closing of Non-Brokered Private Placement
MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, announcing an Initial Closing, it has completed a further Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Further Closing comprised the issuance of 7,300,000 Units (as described below) and raised cash proceeds of $511,000, bringing the total amount raised so far to $1,456,000. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Further Closing(s) of the Placement will be subject to receipt of further subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Under this Non-Brokered Private Placement, the Company intends issue of up to a maximum of 35,714,858 Units at $0.07 per Unit ('Unit') to raise a Maximum amount of $2,500,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant (s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent's warrants (' Agent's Warrant(s) ') equal to 8% of subscriptions introduced by such agent(s). Each Agent's Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement will be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
National Post
21-05-2025
- Business
- National Post
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
Article content MISSISSAUGA, Ontario — MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed Biomedical, a MedX commercial partner in Italy, and Medispa, a leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. Article content Article content This new partnership will facilitate the deployment of MedX's proprietary SIAscope on DermSecure® platform across Medispa's extensive network of pharmacies, medical centers, and wellness facilities, increasing patient access to advanced skin screening and preventive care. Article content 'We are pleased to support our partners Vitamed Biomedical and Medispa in bringing our SIAscope on DermSecure® system to a broader patient base in Italy,' said Mike Druhan, President of Dermatological Services at MedX Health Corp. 'This collaboration is an important milestone in our international expansion strategy and underscores our commitment to enabling early detection of melanoma by a dermatologist through accessible, non-invasive teledermatology.' Article content The SIAscope on DermSecure® system enables rapid, non-invasive imaging of suspicious skin lesions, which are securely transmitted for dermatologist review often within 72 hours dramatically accelerating diagnosis while reducing unnecessary referrals and wait times. The solution has been cleared for clinical use across multiple jurisdictions, including the EU, Canada, the U.S., Australia, and the UK. Article content 'This collaboration with Medispa strengthens our mission to expand the reach of teledermatology in Italy,' said Giuseppe Verderame, CEO of Vitamed Biomedical. 'By integrating MedX's platform into high-traffic and trusted community hubs like pharmacies and wellness centers, we are improving accessibility and empowering individuals with better tools for early skin cancer detection.' Article content Andrea Prina, CEO of Medispa, added: 'This partnership perfectly aligns with Medispa's vision of innovating healthcare delivery through digital technology. By offering MedX's solution through our network, we're providing citizens with fast, reliable access to dermatological screening and reinforcing our commitment to prevention-first health services.' Article content Italy represents a key European growth market for MedX Health, where demand for accessible, specialist-level dermatological screening continues to grow particularly in light of increased awareness of skin cancer risks associated with aging populations and sun exposure. Article content About Vitamed Biomedical Article content Vitamed Biomedical is a provider of advanced medical technologies and a commercial partner of MedX in Italy. The company focuses on distributing innovative healthcare solutions that support early diagnosis and patient-centered care across Italy's public and private healthcare sectors. Article content About Medispa Article content Medispa is an Italian company specializing in digital innovation for prevention and wellness services. With a strong presence in pharmacies, medical clinics, and wellness centers, Medispa is dedicated to delivering integrated, forward-thinking health services for the modern consumer. Article content About MedX Health Corp. Article content MedX Health Corp., headquartered in Ontario, Canada, is a leading developer of non-invasive skin analysis and teledermatology solutions. Its SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free imaging of skin lesions for rapid remote dermatologist assessment. MedX products are cleared for use in Canada, the United States, Europe, Australia, and several other markets. Visit: Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
21-05-2025
- Business
- Business Wire
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), a global leader in teledermatology, is pleased to announce a strategic collaboration in the Italian healthcare market between Vitamed Biomedical, a MedX commercial partner in Italy, and Medispa, a leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. This new partnership will facilitate the deployment of MedX's proprietary SIAscope on DermSecure® platform across Medispa's extensive network of pharmacies, medical centers, and wellness facilities, increasing patient access to advanced skin screening and preventive care. 'We are pleased to support our partners Vitamed Biomedical and Medispa in bringing our SIAscope on DermSecure® system to a broader patient base in Italy,' said Mike Druhan, President of Dermatological Services at MedX Health Corp. 'This collaboration is an important milestone in our international expansion strategy and underscores our commitment to enabling early detection of melanoma by a dermatologist through accessible, non-invasive teledermatology.' The SIAscope on DermSecure® system enables rapid, non-invasive imaging of suspicious skin lesions, which are securely transmitted for dermatologist review often within 72 hours dramatically accelerating diagnosis while reducing unnecessary referrals and wait times. The solution has been cleared for clinical use across multiple jurisdictions, including the EU, Canada, the U.S., Australia, and the UK. 'This collaboration with Medispa strengthens our mission to expand the reach of teledermatology in Italy,' said Giuseppe Verderame, CEO of Vitamed Biomedical. 'By integrating MedX's platform into high-traffic and trusted community hubs like pharmacies and wellness centers, we are improving accessibility and empowering individuals with better tools for early skin cancer detection.' Andrea Prina, CEO of Medispa, added: 'This partnership perfectly aligns with Medispa's vision of innovating healthcare delivery through digital technology. By offering MedX's solution through our network, we're providing citizens with fast, reliable access to dermatological screening and reinforcing our commitment to prevention-first health services.' Italy represents a key European growth market for MedX Health, where demand for accessible, specialist-level dermatological screening continues to grow particularly in light of increased awareness of skin cancer risks associated with aging populations and sun exposure. About Vitamed Biomedical Vitamed Biomedical is a provider of advanced medical technologies and a commercial partner of MedX in Italy. The company focuses on distributing innovative healthcare solutions that support early diagnosis and patient-centered care across Italy's public and private healthcare sectors. About Medispa Medispa is an Italian company specializing in digital innovation for prevention and wellness services. With a strong presence in pharmacies, medical clinics, and wellness centers, Medispa is dedicated to delivering integrated, forward-thinking health services for the modern consumer. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leading developer of non-invasive skin analysis and teledermatology solutions. Its SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free imaging of skin lesions for rapid remote dermatologist assessment. MedX products are cleared for use in Canada, the United States, Europe, Australia, and several other markets. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This media release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. These statements involve risks and uncertainties.
Yahoo
20-05-2025
- Business
- Yahoo
MedX Holdings, Inc. (OTC: MEDH) Announces Record Q1 2025 Revenue and Strategic Advances Across Cannabis, Retail Tech, and Franchise Growth
Austin, Texas, May 20, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MedX Holdings, Inc. (OTC: MEDH) Reports Record Q1 2025 Revenue and Announces Strategic Milestones in Retail Technology, AI, and Cannabis Expansion Austin, TX – May 20, 2025 – MedX Holdings, Inc. (OTC: MEDH), the parent company of Lazydaze + Coffeeshop and Dazed Inc., announced its unaudited financial results for the first quarter of 2025 along with key strategic developments that continue to position the company as a leader in cannabis retail, technology, and lifestyle franchise operations. For the quarter ended March 31, 2025, MedX Holdings delivered its strongest financial performance to date, driven by accelerating revenue growth, solid gross margins, and improved operational efficiency. Revenue more than tripled year-over-year, fueled by expanded retail activity, strategic acquisitions, and increased consumer demand across the Lazydaze franchise network. The company maintained a healthy gross margin profile, improved cost control and strong unit economics. Net income surged to a new high, reflecting a significant turnaround in bottom-line profitability. MedX also reinforced its balance sheet strength, increasing total stockholders' equity while successfully reducing liabilities—a clear signal of momentum and prudent capital management heading into the next phase of expansion. MedX is currently raising $10 million through a convertible note offering to support its next phase of growth. Executives are actively engaging with investors and financials groups , and aniticiapates clsoing the round by end of Q2. The proceeds will be used to complete a full audit, fund capital expenditures, purchase pre-roll manufacturing equipment, and secure flagship retail properties in key markets. The company also announced the launch of an AI-driven commerce initiative, which includes the development of mobile vending machines powered by proprietary artificial intelligence technology and the rollout of AI Budtender and Barista agents on These enhancements are designed to streamline online pickup, delivery, and in-store operations while improving the customer's user experience across current and future Lazydaze locations. In collaboration with Revel Systems and Shift4, MedX is co-developing a first-of-its-kind point-of-sale system tailored for dispensary, hospitality, and retail hybrid environments. This fully customizable platform will ensure compliance with state traceability systems such as METRC and BioTrack. This solution will be offered to other cannabis operators nationwide through Smart Brand Digital, bundled with secure payment processing solutions. MedX also confirmed its active pursuit of licensing and strategic partnerships to establish a consumption lounge in Las Vegas. Additionally, the company's recently acquired operation in Albuquerque, New Mexico, Lazydaze ABQ LLC, is scheduled to begin hemp pre-roll manufacturing in Q2 2025. These products will be distributed through stores in Texas and other future retail markets. Lazydaze is also proud to announce its newest franchise located just blocks away from the University of Texas in Austin, Texas. Hans Enriquez, CEO of MedX Holdings, stated, 'Q1 performance proves our model is working. From record sales, franchise growth, utilizing AI, embracing blockchain and a new POS system built for the future of cannabis retail, we're executing across all fronts and ready to move faster. We are committed to building MedX and Lazydaze into the go-to platform for cannabis hospitality, social experiences, retail technology, and community culture.' About MedX Holdings, Inc. (OTC: MEDH) MedX Holdings is building a portfolio for cannabis retail, hospitality, and technology through its subsidiaries, including Dazed Inc., Smart Brand Digital, and Lazydaze + Coffeeshop. The company is focused on franchise development, cannabis/hemp retail innovation, and regulatory-compliant tech solutions for the industry. Our mission is to deliver exceptional products and unforgettable hospitality experiences through our Lazydaze +Coffeeshop brands and franchises. We are committed to leading the industry by developing and expanding a successful portfolio of licensed and franchised brands. For more information, please visit and Follow us @medxholdings and the CEO @the1onlyhans on X Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially due to various risks and uncertainties. Contact Information:Raji Bhakta- President Operations / IRMedX Holdings, Inc.210 438 2750raji@ ### Attachment MEDH Press Release Phamceutical Sales 5.17.2016 CONTACT: Phone: 877-225-0243 Email: kathy@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
